Physician profile
Frank Young
NPI 1861464091
$2,360.38
in general payments reported to CMS, 2019-2025
30 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $280 · 2021: $290 · 2022: $270 · 2023: $476 · 2024: $386 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $410.83 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $340.56 | 2019-2021 | |
| Abbvie INC. | $186.95 | 2020-2024 | Vraylar |
| Lilly USA, LLC | $181.75 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $179.49 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $147.25 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $101.28 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $95.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $91.94 | 2020-2025 | Eliquis |
| Abbott Laboratories | $63.01 | 2022-2024 | Freestyle Libre 3, Freestyle Libre |
| Allergan, INC. | $57.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.37 | 2022-2024 | |
| Mckesson Medical-Surgical, INC. | $46.66 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $44.25 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.06 | 2019-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $30.34 | 2021 | |
| Bausch Health US, LLC | $30.22 | 2022-2024 | Aplenzin, Wellbutrin |
| Medtronic, INC. | $29.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $29.45 | 2023 | Rexulti |
| Edwards Lifesciences Corporation | $27.99 | 2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $26.47 | 2019-2023 | Breztri |
| Merck Sharp & Dohme LLC | $25.53 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $20.93 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $19.37 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $18.96 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $14.01 | 2019 | |
| Dexcom, INC. | $13.28 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $12.48 | 2021 | |
| Seqirus USA INC | $11.66 | 2022 | |
| Sanofi Pasteur INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.